# GRASPA Treatment for Patients With Acute Myeloblastic Leukemia

> **NCT01810705** · PHASE2 · COMPLETED · sponsor: **ERYtech Pharma** · enrollment: 123 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** GRASPA

## Key facts

- **NCT ID:** NCT01810705
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01810705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01810705, "GRASPA Treatment for Patients With Acute Myeloblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01810705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*